Circadian Time Restricted Eating

Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Nov 16, 2022

Keywords

ClinConnect Summary

This clinical trial, called "Circadian Time Restricted Eating," is investigating how the timing of meals affects overall health, particularly for individuals who are overweight or obese. The researchers want to find out if eating according to our natural body clocks, known as circadian rhythms, can improve heart and metabolic health, as well as help with weight loss. The study will last for 46 days and will involve both at-home and in-laboratory activities to gather information about participants' health.

To participate, individuals should be healthy but overweight or obese, with a body mass index (BMI) of 27 or higher. However, those with certain health issues, like heart disease, diabetes, or sleep disorders, won't be eligible. Participants can expect to follow a specific eating schedule and share data about their health during the study. It's important for potential participants to know that they should not have worked night shifts or traveled across time zones recently, as this could affect their body clock. This study aims to uncover new insights into how when we eat can influence our overall well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Healthy, overweight or obese individuals.
• Exclusion Criteria:
• • 1. Participants must have a body mass index (BMI) greater than or equal to 27 kilograms per meter squared.
• • 2. No history of drug or alcohol dependency. Must be current non-smokers, and are required to have a history of less than 5 pack years of smoking.
• • 3. No history of working irregular day and night hours, regular night work, or rotating shift work for the 1 year prior to the study. In addition to this, individuals must not have traveled across more than 1 time zone during the 3 months prior to the study.
• • 4. Chronobiologic and sleep disorders.
• • 5. Diseases of the cardiovascular system.
• • 6. Hypertension. Individuals will be allowed to be normotensive (resting systolic blood pressure of \<140/90 mmHg, measured on more than one occasion) or uncomplicated stage 1 hypertension (systolic BP between 140 and 159 mmHg or a diastolic BP between 90 and 99 mmHg).
• • 7. Disorders of the respiratory system.
• • 8. Pre-diabetes/Diabetes. For participants who have a fasting blood glucose level that is greater than or equal to 100 mg/dL, the investigators will measure hemoglobin A1c to exclude for diabetes (HbA1c\>5.7%).
• • 9. Disorders of the kidney and urinary tract.
• • 10. Infectious diseases.
• • 11. Disorders of the gastrointestinal system.
• • 12. Disorders of the immune system.
• • 13. Disorders of the hematopoietic system.
• • 14. Neoplastic diseases.
• • 15. Endocrine and metabolic diseases.
• • 16. Neurologic disorders.
• • 17. Must not be participating in another research study that would influence their safe participation in the study.